Compare DIN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | CMPX |
|---|---|---|
| Founded | 1958 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.8M | 371.0M |
| IPO Year | 1994 | 2020 |
| Metric | DIN | CMPX |
|---|---|---|
| Price | $34.15 | $2.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $29.00 | $14.57 |
| AVG Volume (30 Days) | 386.6K | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $879,300,000.00 | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $0.64 | $934.41 |
| P/E Ratio | $60.23 | ★ N/A |
| Revenue Growth | ★ 8.25 | N/A |
| 52 Week Low | $19.58 | $1.61 |
| 52 Week High | $39.68 | $6.88 |
| Indicator | DIN | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 69.38 | 39.97 |
| Support Level | $33.47 | $1.68 |
| Resistance Level | $35.28 | $2.47 |
| Average True Range (ATR) | 1.36 | 0.15 |
| MACD | 0.37 | 0.07 |
| Stochastic Oscillator | 85.59 | 27.12 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.